Equities

Fortress Biotech Inc

Fortress Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.61
  • Today's Change0.035 / 2.23%
  • Shares traded157.38k
  • 1 Year change-27.05%
  • Beta1.6453
Data delayed at least 15 minutes, as of Nov 22 2024 20:47 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).

  • Revenue in USD (TTM)62.50m
  • Net income in USD-57.53m
  • Incorporated2006
  • Employees186.00
  • Location
    Fortress Biotech Inc1111 KANE CONCOURSE, SUITE 301BAY HARBOR ISLANDS 33154United StatesUSA
  • Phone+1 (781) 652-4500
  • Fax+1 (781) 652-4545
  • Websitehttps://www.fortressbiotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ImmuCell Corp23.84m-3.81m32.62m74.00--1.22--1.37-0.4856-0.48563.032.990.53572.3511.43301,746.80-8.56-5.16-9.39-5.5326.7140.04-15.99-12.641.44-6.210.2922---5.909.72-131.56---1.39--
Incannex Healthcare Inc86.00k-23.15m34.76m9.00--5.27--404.14-1.40-1.400.00520.3738------9,555.56---130.12---148.24-----26,922.09-3,421.98----0.00----61.0362.18--73.79--
CEL-SCI Corp0.00-29.10m37.17m43.00--3.87-----0.5806-0.58060.000.15620.00-------100.88-70.19-124.78-78.31-------15,434.150.1793-36.790.5517------13.99--223.59--
Lexaria Bioscience Corp411.01k-4.85m37.70m5.00--3.37--91.72-0.4455-0.44550.04080.64030.0539--2.1682,202.00-63.85-95.67-65.93-96.5898.8376.98-1,185.15-1,612.76---64.960.00---11.43-12.198.31------
Tonix Pharmaceuticals Holding Corp11.29m-135.25m38.16m103.00--0.4282--3.38-52.81-52.810.64770.47680.09640.82914.05109,621.40-115.46-59.46-134.34-65.9220.74---1,197.86-5,126.732.78--0.0972------0.1874--320.57--
Earth Science Tech Inc26.89m2.33m39.78m32.0017.2612.4316.051.480.00760.00760.08780.01056.6523.99201.60840,435.9057.64-37.9879.28--71.3063.878.67-15.481.093.340.0241--24,526.3773.03322.25------
Fortress Biotech Inc62.50m-57.53m43.27m186.00--2.05--0.6924-3.53-3.533.740.7670.45022.166.70336,026.90-88.98-52.50-142.15-99.4660.5563.17-197.64-236.941.06-9.661.31--11.5825.7527.42---9.37--
United-Guardian, Inc.12.31m3.48m44.79m25.0012.863.9412.493.640.75850.75852.682.480.96844.747.44492,490.8027.4129.8431.5734.3953.4355.3128.3028.796.02--0.0097.37-14.28-4.140.4616-9.9217.19-19.73
Verrica Pharmaceuticals Inc9.21m-84.99m45.14m100.00------4.90-1.83-1.830.1979-0.74670.14161.674.6792,100.00-130.68-55.75-174.03-78.3374.08---922.81-754.941.22-10.163.82---43.27---173.59--5.65--
SCYNEXIS Inc8.57m-36.44m45.16m29.00--0.7715--5.27-0.756-0.7560.1771.540.0692--3.61295,379.30-29.44-30.02-35.54-36.35-71.42---425.41-86.76----0.1843--2,652.72252.64206.74------
Immix Biopharma Inc0.00-21.89m46.12m14.00--2.63-----0.8536-0.85360.000.63870.00----0.00-92.58---114.95--------------0.00-------87.44------
Odonate Inc0.00-102.07m49.87m137.00--1,839.01-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
BGM Group Ltd29.87m-7.86m50.59m298.00--1.15--1.69-1.10-1.104.186.070.52373.7325.96100,236.40-14.432.71-17.013.862.9211.66-27.562.726.06-0.75270.0026.11-28.35-1.60-822.64--12.86--
Data as of Nov 22 2024. Currency figures normalised to Fortress Biotech Inc's reporting currency: US Dollar USD

Institutional shareholders

11.54%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2024623.02k2.26%
Cambridge Investment Research Advisors, Inc.as of 30 Sep 2024554.40k2.01%
Rosalind Advisors, Inc.as of 30 Sep 2024502.83k1.82%
Acadian Asset Management LLCas of 30 Sep 2024482.60k1.75%
Shikiar Asset Management, Inc.as of 30 Sep 2024235.97k0.86%
Envestnet Asset Management, Inc.as of 30 Sep 2024183.95k0.67%
Geode Capital Management LLCas of 30 Sep 2024168.61k0.61%
PVG Asset Management Corp.as of 30 Jun 2024155.68k0.57%
Nantahala Capital Management LLCas of 30 Sep 2024153.15k0.56%
B. Riley Wealth Advisors, Inc.as of 30 Jun 2024120.81k0.44%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.